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November 20/27, 2012:2255–604.8% in the ICD arm (the relevant comparator group) and 6.3% in the
CRT-D hypo-responder group and claim that hypo-responders had
“almost double the annualized mortality rate” is incorrect and statis-
tically unsound.
We do not agree with the statements of Dr. Lim that our study
“underestimated the adverse effects of CRT in ‘hypo-responders’”
or that the 49 deaths not accounted for in our cohort infers a
higher proportion/mortality rate of “hypo-responders.” We would
like to clarify any misunderstandings from the inferences of Dr.
Lim. Of the other 49 deaths in the CRT-D arm not included in
our analysis, 23 of 337 excluded patients (6.8%) died during the
first year of follow-up, and 26 of 337 excluded patients (7.7%) died
after the first year. By definition, the 337 excluded patients had
higher rates of death, because some patients died before or
otherwise did not meet the inclusion criteria of our cohort of both
baseline and 12-month follow-up echocardiograms. These data
indicate that patients who had not died but missed their 12-month
echocardiogram might be at greater risk of subsequent poor
outcomes, perhaps from factors associated with incomplete
follow-up (e.g., illness). Although selection bias might have been
introduced, we found no other feasible way to perform an analysis
with LVEF change, because serial LVEF measurements were
conditional on having survived to 1 year. We acknowledged this
potential limitation in our paper (1).
Finally, our study identified characteristics including left
bundle branch block and longer QRS duration (150 ms)
associated with super-response to CRT-D therapy, and thus we
agree with Dr. Lim that these findings highlight the possibility
that patients with the converse might not derive similar
benefits, despite incurring the risk and costs of this therapy.
However, to recommend withholding CRT-D therapy in a
subgroup of otherwise eligible patients without prospective
studies to support this practice might be ill-advised. As a result,
we believe that the hypotheses generated by these observations
should be tested in future studies.
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Absence of Cardiovascular
Implantable Electronic
Device Infection in
Remote Implantations
Demonstrated by Fluorine-18
Positron Emission Tomography
We read with strong interest the paper by Sarrazin et al. (1), which
reported on the utility of Fluorine-18 (18F-FDG) positron emission
omography (PET)/computed tomography (CT) for identification of
ardiovascular implantable electronic device (CIED) infections. As
oted in the article, the diagnosis of CIED infections can be very
hallenging, and unnecessary device extraction can expose the patient
o significant morbidity and mortality (2,3). The paper suggested a
igh sensitivity and specificity of 18F-FDG PET/CT in differentiat-
ing pocket and/or lead infections from non-infected devices older
than 6 months. However, the control group in the study was small
(only 10 patients), and the prevalence of increased nonspecific
18F-FDG uptake in not-infected CIED patients is unknown. To
urther validate the negative control, we decided to review 69
18F-FDG PET/CT scans performed on patients with remote im-
plantable cardioverter-defibrillator (ICD) insertion for elective rea-
sons. All patients with remote ICD insertion and no clinical/
laboratory evidence of infection undergoing 18F-FDG PET/CT in
reparation for ventricular tachycardia ablation from 2006 to 2011
ere identified in our institution. Semi-quantitative assessment of
18F-FDG uptake was assessed in 4 sites (generator pocked, innomi-
ate vein, superior vena cava, and intracardiac space [right atrium/
entricle]). Uptake was categorized in none (score  0), mild
thoracic background activity; score  1), moderate (thoracic
ackground activity; score  2), and severe hypermetabolism (very
ntense uptake; score  3). Evaluation of 69 contiguous patients
evealed 18F-FDG signal uptake scores of 0 in all segments. Thus, our
data further strengthens the validity of negative controls in the current
paper and supports a potential use of 18F-FDG PET/CT in differ-
entiating patients with CIED infection from chronic implant
changes, providing a new path in management of CIED infection.
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Reply
We thank Drs. Beck and Dickfield for their interest in our paper (1)
and their additional contribution to this topic with their new data.
In their letter to the editor, they reported their data on 69 patients
with remote implantable cardioverter-defibrillator implantation and
no clinical evidence of device infection, who all underwent fluorine-18
fluorodeoxyglucose (18F-FDG) positron emission tomography before
ventricular tachycardia ablation. They found no significant 18F-FDG
uptake around the generator or leads in these patients, confirming the
absence of abnormalities in the control group and the usefulness of
this technology for ruling out cardiovascular implantable electronicdevice infection. Indeed, we think that this information strengthens
the data from our small control group. More studies are still required
to determine possible causes for false-positive and false-negatives cases.
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